TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02500381

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP-4045
Description: SRP-4045 solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4045
Description: SRP-4045 solution for IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP-4053
Description: SRP-4053 solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4053
Description: SRP-4053 solution for IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
Study: NCT00584883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT 510
Description: ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
Study: NCT02684279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4, 6, 8 mg flexibly dosed once daily
Study: NCT04014361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Tablet
Description: Administered orally.
Study: NCT02338349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Study: NCT02593786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02620267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Stimulation
Description: Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
Study: NCT02789735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active laser therapy
Description: Laser therapy at predetermined sites

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser therapy
Description: Sham therapy at predetermined sites
Study: NCT04534504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SG-JJB
Description: Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SG-JJB
Description: Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
Study: NCT03193788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
Study: NCT05829928

Intervention type: DIAGNOSTIC_TEST
Intervention: Infectious Disease Testing
Description: Participants will undergo infectious disease testing.

Intervention type: PROCEDURE
Intervention: Gonadal Tissue Removal
Description: Removal of gonadal tissue will be done through a surgical procedure.
Study: NCT02823808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NESINA ACT TAB. 25/15mg
Description: Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARYL-M TAB. 2/500mg
Description: Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Study: NCT01019980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Diclofenac potassium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen
Study: NCT01152762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Respiratory Physiotherapy
Description: Standardized Respiratory Physiotherapy during 6 months
Study: NCT03947125

Intervention type: DRUG
Intervention: Buprenorphine transdermal patch on knee joint
Description: Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.

Intervention type: DRUG
Intervention: Buprenorphine transdermal patch on knee joint
Description: Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
Study: NCT01608542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200mg
Description: oral tablet
Study: NCT01301651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: 30 minute each time, 2 times per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: 30 minute each time, 2 times per week for 6 weeks.
Study: NCT02885805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: 2.00 mg/cm2 ± 0.04 mg/cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Study: NCT06352047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of positioning on respiratory functions of preterm infants after extubation.
Description: Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of positioning on respiratory functions of preterm infants after extubation.
Description: Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
Study: NCT01979835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GyneFix Viz
Description: insertion of GyneFix Viz and measurment of the SA distance
Study: NCT04038853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25-Dihydroxyvitamin D
Description: 1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to the study intervention drug
Study: NCT00671554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melaxin (autologous dendritoma vaccine) and BCG
Description: Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
Study: NCT04272970

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Validation of a new gene / protein variant implicated in familial CT
Description: Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Validation of a new gene / protein variant implicated in familial CT
Description: Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
Study: NCT01479829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a manufactured capsule with no active ingredient
Study: NCT00601250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: linagliptin
Description: Patients receive linagliptin 5 mg tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: Patients receive linagliptin 5 mg tablets once daily
Study: NCT00708175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Study: NCT00985322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor Ramipril
Description: The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-RAS inhibitor antihypertensive therapy
Description: Blood Pressure lowering regimen not including RAS inhibitors
Study: NCT03217149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heliox combined with MV
Description: heliox combined with MV is given to infant with ARDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MV
Description: MV is given to infant with ARDS
Study: NCT03641105

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: detect the contents of glucose metabolism molecules using mass spectrum
Study: NCT05906823

Intervention type: OTHER
Intervention: Detection of pleural effusion
Description: Detection of pleural effusion

Intervention type: OTHER
Intervention: Detection of pleural effusion
Description: Detection of pleural effusion

Intervention type: OTHER
Intervention: Detection of pleural effusion
Description: Detection of pleural effusion
Study: NCT01578967

Intervention type: DRUG
Group type: OTHER
Intervention: Brentuximab vedotin
Description: IV, 1.8mg/kg, every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Study: NCT00527254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine system
Description: Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
Study: NCT03722056

Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
Study: NCT02944994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unified protocol
Description: This is a transdiagnostic cognitive behavioral therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: This arm will reflect typical care received in routine mental health care
Study: NCT04237922

Intervention type: DRUG
Intervention: Prasugrel 10mg
Description: Prasugrel 10mg dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg dispensing claim is used as the reference group
Study: NCT00650572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-380, HER2 inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT01685424

Intervention type: DRUG
Intervention: Etoricoxib
Description: As per routine clinical practice in the United Kingdom

Intervention type: DRUG
Intervention: Etoricoxib
Description: As per routine clinical practice in the United Kingdom

Intervention type: DRUG
Intervention: Etoricoxib
Description: As per routine clinical practice in the United Kingdom
Study: NCT03759977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
Study: NCT00809081

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral Feeding and Total Parental Support
Description: Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Enteral Feeding and Total Parental Support
Description: Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)
Study: NCT00447382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: NN304 injected s.c. (under the skin). Given as basal insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. (under the skin). Given as bolus insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin). Given as bolus insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: NN729 injected s.c. (under the skin). Given as basal insulin
Study: NCT01094119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heated pad
Description: patients will be warmed with a heated pad during surgery.
Study: NCT03865901

Intervention type: DIAGNOSTIC_TEST
Intervention: Mellitus GCD59 Test
Description: An ELISA for screening for the risk of gestational diabetes
Study: NCT00308269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Bolus
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Bolus
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Bolus
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Infusion
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Infusion
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Study: NCT04661501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloMax
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DermACELL
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flex HD
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
Study: NCT01862302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Study: NCT06323200

Intervention type: PROCEDURE
Intervention: lymphaticovenous anastomosis
Description: The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).

Intervention type: PROCEDURE
Intervention: lymphaticovenous anastomosis
Description: The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
Study: NCT02018757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE containing As2O3
Description: transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TACE containing placebo
Description: transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Study: NCT01674751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-ordering program
Description: During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time.

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-ordering program
Description: During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time.